Payment overview · 2025
General Payments
$423.45
19 reported records · 10 companies
Healthcare provider profile · identity verified
Thomas Scott Royster, MD
Allopathic & Osteopathic Physicians|Family Medicine · MADISON, AL · NPI 1730221441
Verified facts
What the public records show
CMS Open Payments records show Thomas Scott Royster, MD received $423.45 in general payments during 2025 across 19 reported records.
Antares Pharma, Inc. accounted for 37.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Synthroid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Vraylar by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $160.13 | 37.8% | 7 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $60.07 | 14.2% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $52.40 | 12.4% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $26.15 | 6.2% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $25.21 | 6.0% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $23.34 | 5.5% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $22.36 | 5.3% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $21.89 | 5.2% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $17.65 | 4.2% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $14.25 | 3.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $423.45 | 19 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $160.13 | 7 | 2025 |
Source payment records
|
|||||
| JATENZO Normalized: jatenzo |
Drug | TOLMAR, INC. | $60.07 | 3 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $52.40 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $26.15 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $26.01 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $25.21 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $23.34 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $23.34 | 1 | 2025 |
Source payment records
|
|||||
| TLANDO Normalized: tlando |
Drug | Antares Pharma, Inc. | $23.14 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $22.36 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $21.89 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $21.89 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $17.65 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $17.65 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $14.25 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 52 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 95 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
95 | 19 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
78 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
52 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 392 | 110 |
| Pravastatin Sodium | Pravastatin Sodium | 338 | 106 |
| Atorvastatin Calcium | Atorvastatin Calcium | 316 | 94 |
| Alprazolam | Alprazolam | 287 | 39 |
| Amlodipine Besylate | Amlodipine Besylate | 277 | 85 |
| Losartan Potassium | Losartan Potassium | 271 | 72 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 193 | 35 |
| Lorazepam | Lorazepam | 192 | 33 |
| Metformin Hcl Er | Metformin Hcl | 191 | 59 |
| Omeprazole | Omeprazole | 190 | 55 |
| Tamsulosin Hcl | Tamsulosin Hcl | 168 | 47 |
| Montelukast Sodium | Montelukast Sodium | 167 | 50 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 163 | 51 |
| Tramadol Hcl | Tramadol Hcl | 163 | 36 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 156 | 45 |
| Famotidine | Famotidine | 155 | 47 |
| Gabapentin | Gabapentin | 154 | 33 |
| Pantoprazole Sodium | Pantoprazole Sodium | 148 | 42 |
| Metoprolol Succinate | Metoprolol Succinate | 138 | 43 |
| Clonazepam | Clonazepam | 135 | 24 |
| Hydrochlorothiazide | Hydrochlorothiazide | 123 | 34 |
| Zolpidem Tartrate | Zolpidem Tartrate | 123 | 15 |
| Lisinopril | Lisinopril | 118 | 39 |
| Duloxetine Hcl | Duloxetine Hcl | 105 | 28 |
| Escitalopram Oxalate | Escitalopram Oxalate | 96 | 29 |
| Synthroid | Levothyroxine Sodium | 95 | 19 |
| Azelastine Hcl | Azelastine Hcl | 94 | 49 |
| Trazodone Hcl | Trazodone Hcl | 93 | 30 |
| Pregabalin | Pregabalin | 87 | 17 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 83 | 17 |
| Methylprednisolone | Methylprednisolone | 82 | 64 |
| Metformin Hcl | Metformin Hcl | 81 | 23 |
| Sertraline Hcl | Sertraline Hcl | 80 | 24 |
| Simvastatin | Simvastatin | 80 | 26 |
| Jardiance | Empagliflozin | 78 | 17 |
| Allopurinol | Allopurinol | 74 | 19 |
| Ezetimibe | Ezetimibe | 71 | 18 |
| Doxycycline Hyclate | Doxycycline Hyclate | 69 | 46 |
| Meloxicam | Meloxicam | 69 | 21 |
| Quetiapine Fumarate | Quetiapine Fumarate | 67 | 12 |
| Glimepiride | Glimepiride | 66 | 15 |
| Buspirone Hcl | Buspirone Hcl | 64 | 15 |
| Furosemide | Furosemide | 64 | 23 |
| Prednisone | Prednisone | 61 | 39 |
| Carvedilol | Carvedilol | 57 | 16 |
| Potassium Chloride | Potassium Chloride | 57 | 19 |
| Januvia | Sitagliptin Phosphate | 56 | suppressed |
| Spironolactone | Spironolactone | 54 | 13 |
| Mounjaro | Tirzepatide | 52 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 51 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 49 | 13 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 47 | 23 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 47 | 33 |
| Diazepam | Diazepam | 47 | suppressed |
| Telmisartan | Telmisartan | 47 | 13 |
| Atenolol | Atenolol | 46 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 46 | 15 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 46 | 40 |
| Bupropion Xl | Bupropion Hcl | 45 | 14 |
| Temazepam | Temazepam | 45 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 43 | 11 |
| Celecoxib | Celecoxib | 41 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 41 | 12 |
| Testosterone | Testosterone | 40 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 39 | suppressed |
| Estradiol | Estradiol | 38 | 12 |
| Eliquis | Apixaban | 36 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 36 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 35 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 34 | 16 |
| Methocarbamol | Methocarbamol | 34 | 11 |
| Ondansetron Odt | Ondansetron | 34 | 17 |
| Valacyclovir | Valacyclovir Hcl | 34 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 33 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 33 | suppressed |
| Myrbetriq | Mirabegron | 33 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 32 | suppressed |
| Ozempic | Semaglutide | 32 | 11 |
| Candesartan Cilexetil | Candesartan Cilexetil | 30 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 30 | suppressed |
| Mupirocin | Mupirocin | 30 | 24 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 28 | suppressed |
| Zaleplon | Zaleplon | 28 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 27 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 26 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 26 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 26 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 26 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 25 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 25 | suppressed |
| Finasteride | Finasteride | 24 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 24 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 24 | suppressed |
| Trulicity | Dulaglutide | 24 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 23 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 23 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 23 | suppressed |
| Irbesartan | Irbesartan | 22 | suppressed |
| Naproxen | Naproxen | 22 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 22 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 21 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 21 | suppressed |
| Cephalexin | Cephalexin | 20 | 18 |
| Mirtazapine | Mirtazapine | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Topiramate | Topiramate | 20 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 19 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 19 | suppressed |
| Torsemide | Torsemide | 19 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Rybelsus | Semaglutide | 18 | suppressed |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 15 | suppressed |
| Eszopiclone | Eszopiclone | 15 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 15 | suppressed |
| Premarin | Estrogens, Conjugated | 15 | suppressed |
| Azithromycin | Azithromycin | 14 | 12 |
| Memantine Hcl | Memantine Hcl | 14 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 13 | suppressed |
| Pentoxifylline | Pentoxifylline | 13 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 13 | suppressed |
| Armodafinil | Armodafinil | 12 | suppressed |
| Carisoprodol | Carisoprodol | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 12 | suppressed |
| Vraylar | Cariprazine Hcl | 12 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Clomipramine Hcl | Clomipramine Hcl | 11 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Jantoven | Warfarin Sodium | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Sotalol | Sotalol Hcl | 11 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $423.45 · 19 records | Antares Pharma, Inc. | AREXVY, Auvelity, GEMTESA, JATENZO, Kerendia, MOUNJARO, OTEZLA, REPATHA, SHINGRIX, SYNTHROID, TLANDO, The Cologuard Plus Collection Kit, UBRELVY, XYOSTED, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error